For the first time in over two decades, a breakthrough in pain management has arrived—without the shadow of opioid addiction.

The newly approved Journavx delivers powerful relief for acute pain by targeting the peripheral nervous system—not the brain. This innovative mechanism significantly reduces the risk of dependence, offering a safer, science-backed alternative for patients and providers alike.

At Be Well Health, we are proud to have contributed to this medical advancement through our participation in both Phase 2 and Phase 3 clinical trials. Our heartfelt thanks go out to the dedicated volunteers who made this progress possible.

Click here to learn more about this groundbreaking development.

Together, we’re helping to rewrite the future of pain care—without opioids.

Mark Carlson, MD, Medical Director